Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Jack

Showing results (71-80 of 594) with videos related to

Pageof 60
Sort By:
Cancer Research|October 19, 2014
Unique molecular landscapes in cancer: implications for individualized, curated drug combinationsJennifer Wheler, J Jack Lee, Razelle Kurzrock
Contemporary Clinical Trials|December 3, 2014
Simulation study for evaluating the performance of response-adaptive randomizationYining Du, Xuan Wang, J Jack Lee
Statistics in Medicine|June 8, 2017
BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpointsHeng Zhou, J Jack Lee, Ying Yuan
Clinical Trials (London, England)|May 22, 2014
Adaptive designs for identifying optimal biological dose for molecularly targeted agentsYong Zang, J Jack Lee, Ying Yuan
Journal of the American Statistical Association|December 15, 2025
Posterior Predictive Design for Phase I Clinical TrialsChenqi Fu, Shouhao Zhou, J Jack Lee
Journal of Statistical Planning and Inference|January 3, 2015
Comparison of Bayesian Sample Size Criteria: ACC, ALC, and WOCJing Cao, J Jack Lee, Susan Alber
Journal of the Royal Statistical Society. Series C, Applied Statistics|November 22, 2013
Phase II trial design with Bayesian adaptive randomization and predictive probabilityGuosheng Yin, Nan Chen, J Jack Lee
Statistics in Medicine|October 18, 2019
A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapiesYanhong Zhou, J Jack Lee, Ying Yuan
Journal of Clinical Pathology|February 3, 2000
Tissue banks in NHS histopathology laboratories and the Consensus StatementC Womack, N Gray, S J Jack
Endocrinology|March 1, 1996
The Drosophila insulin receptor is required for normal growthC Chen, J Jack, R S Garofalo
Pageof 60

Showing results (71-80 of 594) with videos related to

Sort By:
Pageof 60
Cancer Research|October 19, 2014
Unique molecular landscapes in cancer: implications for individualized, curated drug combinationsJennifer Wheler, J Jack Lee, Razelle Kurzrock
Contemporary Clinical Trials|December 3, 2014
Simulation study for evaluating the performance of response-adaptive randomizationYining Du, Xuan Wang, J Jack Lee
Statistics in Medicine|June 8, 2017
BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpointsHeng Zhou, J Jack Lee, Ying Yuan
Clinical Trials (London, England)|May 22, 2014
Adaptive designs for identifying optimal biological dose for molecularly targeted agentsYong Zang, J Jack Lee, Ying Yuan
Journal of the American Statistical Association|December 15, 2025
Posterior Predictive Design for Phase I Clinical TrialsChenqi Fu, Shouhao Zhou, J Jack Lee
Journal of Statistical Planning and Inference|January 3, 2015
Comparison of Bayesian Sample Size Criteria: ACC, ALC, and WOCJing Cao, J Jack Lee, Susan Alber
Journal of the Royal Statistical Society. Series C, Applied Statistics|November 22, 2013
Phase II trial design with Bayesian adaptive randomization and predictive probabilityGuosheng Yin, Nan Chen, J Jack Lee
Statistics in Medicine|October 18, 2019
A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapiesYanhong Zhou, J Jack Lee, Ying Yuan
Journal of Clinical Pathology|February 3, 2000
Tissue banks in NHS histopathology laboratories and the Consensus StatementC Womack, N Gray, S J Jack
Endocrinology|March 1, 1996
The Drosophila insulin receptor is required for normal growthC Chen, J Jack, R S Garofalo
Pageof 60